Cannabis Products can only be commercialised by pharmacies (that do not compound pharmaceuticals) or drugstores.
Cannabis sativa L remains, however, listed as a plant that cannot be cultivated, harvested, exploited, imported, exported, traded, extracted, handled or used in Brazil. There are currently bills of law under review in National Congress to remove Cannabis Sativa L as a prohibited plant, but there is no estimate of when and how those bills will be passed into law. In the current legal context, activities involving Cannabis sativa L are viewed as criminal conduct, with the exception of plant cultivation and harvest for scientific or medicinal purposes, authorised by the Ministry of Health for a determined period of time.
• must primarily have CDB and THC; 
As defined in RDC 327 of 2019, ‘Cannabis Product’ refers to any product manufactured for medical use that contains, as active ingredients only, Cannabis sativa L plant derivatives or phytopharmaceuticals.
As cultivation of Cannabis sativa L is still prohibited in Brazil, local manufacturers must import the active ingredient in the form of a plant derivative, phytopharmaceutical, bulk or industrialised product.
• cannot contain substances that may be potentially toxic at the dosages being used;
The Sanitary Authorisation for manufacturing and/or importation of Cannabis Products is granted by ANVISA via a simplified procedure, initiated upon prior application made by the interested company. This is provided that the Cannabis Product satisfies the requirements set forth in RDC 327 of 2019 regarding quality control, labelling, packaging and traceability of the product, and also that the applicant itself meets the regulatory requirements.
Here on the blog, we have already talked a lot about reasons for adopting self-cultivation, and even cleared up doubts about the topic with the lawyers from Rede Reforma. If this option sounds better to you, you can contact a trusted attorney and apply for individual Habeas Corpus to protect yourself under the law.
But this situation is far from ideal: imported products are out of reach for most of the Brazilian population, half of whom live on just R$ 413 per month (less than U$ 100). The price of Mevatyl, the main imported medication here in the country, is R $ 2,896.70, with slight variations to more or less. To date, only one national company has received authorization to manufacture products from cannabis.
The Drug Law of 2006, was responsible for banning substances like Cannabis here in the country. In 2015, the National Health Surveillance Agency (Anvisa) authorized, through RDC 17/2015, the exceptional import of cannabidiol-based products, in association with other cannabinoids, by individuals, for their own use, with the prescription of a legal professional enabled, for health treatment.
Search for an association:
So we believe that current regulations make treatment with therapeutic cannabis practically unsustainable, and we need the means to change all of that.
This process approved by Anvisa may not be ideal for the entire population. Here in Brazil, not everyone has a financial situation that allows the import of a product based on cannabis (which can cost more than 3 thousand reais per unit). Others do not have access to a medical network that supports treatment. In such cases, our advice is:
The first thing you should do is consult a doctor who specializes in your case. Thus, he will make an assessment and guide your treatment. He will also give you the prescription, necessary to buy the medication or enter the import process at Anvisa.
Proof of address.